Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA H1047L |
Therapy | Palbociclib |
Indication/Tumor Type | oral squamous cell carcinoma |
Response Type | decreased response |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA H1047L | oral squamous cell carcinoma | decreased response | Palbociclib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with Ibrance (palbociclib) resulted in sustained tumor growth, but increasing tumor volume over time with treatment in oral squamous cell carcinoma cell line xenograft models harboring PIK3CA H1047L (PMID: 31516747). | 31516747 |
PubMed Id | Reference Title | Details |
---|---|---|
(31516747) | Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance. | Full reference... |